欣融國際(01587.HK):田野股份委任上海欣融為其品牌獨家代理商
格隆匯 3 月 9日丨欣融國際(01587.HK)發佈公吿,有關公司收購田野創新股份有限公司(目標公司,其股份在新三板上市(股份代號:832023))約11.72%的股權。2021年3月5日,公司全資附屬公司上海欣融食品原料有限公司與目標公司訂立代理銷售協議,據此,目標公司同意委任上海欣融為其“果言果語”品牌名稱項下水果濃漿產品的獨家代理商,期限為三年。
根據協議,於期限三年內的分銷目標應分別為人民幣3,000萬元、人民幣4,000萬元及人民幣5,000萬元,且各方應每年參照(其中包括)上一年度的實際表現,審查及/或修訂該等分銷目標。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.